2024
Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations
Jayakrishnan R, Kwiatkowski D, Rose M, Nassar A. Topography of mutational signatures in non-small cell lung cancer: emerging concepts, clinical applications, and limitations. The Oncologist 2024, 29: 833-841. PMID: 38907669, PMCID: PMC11449018, DOI: 10.1093/oncolo/oyae091.Peer-Reviewed Original ResearchMutational signaturesNon-small cell lung cancerBase substitutionsNon-small lung cancerCell lung cancerLung cancerSingle base substitutionsDoublet base substitutionsResponse to personalized treatmentGenomics effortsMutational signature analysisGenesis of cancerLoss of mismatch repairResponse to therapyMutational processesDamaged DNAAPOBEC activityMismatch repairRepair mechanismsTumor evolutionEndogenous processesMutationsPersonalized treatmentCancerTobacco smokeOutcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation
Su D, Rehman S, Wang K, Deng Y, Rose M, Dosani T, Kunstman J. Outcomes Following Implementation of an Electronic Model for Perioperative Hematologic Consultation. Journal Of Surgical Research 2024, 301: 10-17. PMID: 38905768, DOI: 10.1016/j.jss.2024.04.033.Peer-Reviewed Original ResearchHematology consultationSingle-center retrospective studyClavien-Dindo classificationVA Connecticut Healthcare SystemAssess operative outcomesTime to resolutionPrimary outcome measureE-consultationOperative morbidityPostoperative transfusionHematologic complicationsSurgical outcomesNo significant differenceRetrospective studyProcedural dataOperative outcomesProcedural outcomesStudy cohortPatient characteristicsConsult volumeSecondary outcomesHematologic issuesAssociated with changesReferral patternsSurgerySystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights
Rose M, Kennedy E, Abou-Alfa G, Finn R, Gade T, Kelley R, Taddei T, Gordan J. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncology Practice 2024, 20: 1035-1039. PMID: 38662970, DOI: 10.1200/op.24.00189.Peer-Reviewed Original ResearchSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update
Gordan J, Kennedy E, Abou-Alfa G, Beal E, Finn R, Gade T, Goff L, Gupta S, Guy J, Hoang H, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb A, Kelley R, Kortmansky J, Leaf A, Remak W, Sohal D, Taddei T, Wilson Woods A, Yarchoan M, Rose M. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. Journal Of Clinical Oncology 2024, 42: 1830-1850. PMID: 38502889, DOI: 10.1200/jco.23.02745.Peer-Reviewed Original ResearchTyrosine kinase inhibitorsAdvanced hepatocellular carcinomaSecond-line therapyFirst-line treatmentRandomized controlled trialsHepatocellular carcinomaSystemic therapyFirst-lineChild-Pugh class A liver diseaseEastern Cooperative Oncology Group performance status 0Child-Pugh class A patientsSecond-line therapy optionsFirst-line settingPerformance status 0Third-line therapyFirst-line therapyClass A patientsEvidence-based guidelinesTolerated sorafenibStatus 0A patientsMechanism of actionTherapy optionsClinical decision-makingGuideline update
2023
Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Akgun K, Cain H, Rose M. Multiple Annual Low Dose CT Scans Needed to Detect Malignancy: Number Needed to Scan 蠅4. 2023, a2732-a2732. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2732.Peer-Reviewed Original ResearchDisparities in Lung Cancer Screening in a Sample of Veterans
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Cain H, Akgun K. Disparities in Lung Cancer Screening in a Sample of Veterans. 2023, a2733-a2733. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2733.Peer-Reviewed Original ResearchTime to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening
Bernstein E, DeRycke E, Han L, Bastian L, Bade B, Lerz K, Kravetz J, Carino M, Rose M, Akgun K, Cain H. Time to Diagnosis and Treatment of Non-small Cell Lung Cancer in Patients Undergoing Lung Cancer Screening. 2023, a2734-a2734. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2734.Peer-Reviewed Original ResearchMyelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments
Rose M, Zeidan A. Myelodysplastic Syndromes/Neoplasms—Insights Into Pathogenesis Leading to Improved Classification, Risk Stratification, and Treatments. The Cancer Journal 2023, 29: 109-110. PMID: 37195765, DOI: 10.1097/ppo.0000000000000663.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2022
A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut
Xiang J, Dosani T, Hauser R, Cosentino D, Merchant N, Rose M. A Multidisciplinary Quality Improvement Project to Improve Appropriate Inherited Thrombophilia Testing at VA Connecticut. Blood 2022, 140: 7864-7865. DOI: 10.1182/blood-2022-168044.Peer-Reviewed Original Research
2021
Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience.
Xiang J, Roy A, Summers C, Delvy M, O'Donovan J, Christensen J, Perry L, Connery D, Rose M, Chao H. Improving hematology/oncology clinical research recruitment via universal prescreening: The VA Connecticut (VACT) Cancer Center experience. Journal Of Clinical Oncology 2021, 39: 79-79. DOI: 10.1200/jco.2020.39.28_suppl.79.Peer-Reviewed Original ResearchLung cancer patientsCancer CenterClinical research recruitmentStudy enrollmentCancer patientsClinical trialsPotential eligibilityEligibility criteriaNew lung cancer patientsResearch enrollmentPotential study patientsCancer Center experienceTherapeutic clinical trialsNumber of patientsDiagnosis of cancerResearch recruitmentEligible patientsMalignancy workupPrimary oncologistStudy patientsChart reviewClinic visitsGenitourinary cancersPatient demographicsCenter experience"Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US Veterans
Bade B, DeRycke E, Kunitomo Y, Lerz K, Skanderson M, Rose M, DiDomenico P, Conti M, Taylor C, Crothers K, Federman D, Haskell S, Bean-Mayberry B, Brandt C, Bastian L, Akgun K, Cain H. "Lost to Follow-Up?" Barriers to Lung Cancer Screening Adherence in US Veterans. 2021, a4775-a4775. DOI: 10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a4775.Peer-Reviewed Original Research
2020
Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
Deininger M, Shah N, Altman J, Berman E, Bhatia R, Bhatnagar B, DeAngelo D, Gotlib J, Hobbs G, Maness L, Mead M, Metheny L, Mohan S, Moore J, Naqvi K, Oehler V, Pallera A, Patnaik M, Pratz K, Pusic I, Rose M, Smith B, Snyder D, Sweet K, Talpaz M, Thompson J, Yang D, Gregory K, Sundar H. Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2020, 18: 1385-1415. PMID: 33022644, DOI: 10.6004/jnccn.2020.0047.Peer-Reviewed Original Research
2019
Multicenter phase II trial of RRx-001 in previously treated SCLC.
Morgensztern D, Rose M, Morris J, Ma P, Brzezniak C, Zeman K, Padmanabhan A, Hirth J, Spira A, Wong E, Padda S, Waqar S. Multicenter phase II trial of RRx-001 in previously treated SCLC. Journal Of Clinical Oncology 2019, 37: e20104-e20104. DOI: 10.1200/jco.2019.37.15_suppl.e20104.Peer-Reviewed Original ResearchSmall cell lung cancerRRx-001Partial responseStable diseaseOverall survivalPrior linesCommon treatment-emergent adverse eventsSingle-arm phase II studyArm phase II studyMulticenter phase II trialTreatment-emergent adverse eventsPhase II studyPhase II trialPlatinum-resistant diseaseCell lung cancerOverall response rateTreat populationII trialPrimary endpointAdverse eventsEtoposide chemotherapyII studyComplete responsePlatinum therapyLung cancer
2018
Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma
Giri S, Wong E, Rose M, Wadia R, Park L, Justice A, Neparidze N. Impact of HIV on Clinical Presentation and Outcomes of Individuals with Multiple Myeloma. Blood 2018, 132: 3162. DOI: 10.1182/blood-2018-99-115633.Peer-Reviewed Original ResearchVeterans Aging Cohort StudyMultiple myelomaEM diseaseUninfected patientsClinical characteristicsLytic lesionsOutcome of MMRisk of MMImpact of HAARTRole of HAARTStage 3 diseaseSymptomatic multiple myelomaTime of diagnosisAggressive clinical courseAging Cohort StudyClinical outcome dataCourse of diseasePlasma cell disordersDurie-Salmon stageVeterans Health AdministrationImpact of HIVSignificant differencesStage 1High rateStage 2QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer.
Padda S, Brzezniak C, Waqar S, Wakelee H, Ma P, Rose M, Reid T, Spira A, Wong E, Zeman K, Oronsky B, Abrouk N, Morgensztern D. QUADRUPLE THREAT: A phase II trial of RRx-001 followed by etoposide-platinum re-challenge in previously treated small cell lung cancer. Journal Of Clinical Oncology 2018, 36: e20575-e20575. DOI: 10.1200/jco.2018.36.15_suppl.e20575.Peer-Reviewed Original Research
2017
Concurrent Care and Aggressive End-of-Life Lung Cancer Care
Presley C, Han L, O'leary J, Chao H, Shamas T, Kerin A, Rose M, Gross C. Concurrent Care and Aggressive End-of-Life Lung Cancer Care. Journal Of Thoracic Oncology 2017, 12: s1545. DOI: 10.1016/j.jtho.2017.06.058.Peer-Reviewed Original Research
2014
Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction
Neparidze N, Cecchini M, Wong E, Rose M. Electronic Hematology Consultations at Veterans Affairs (VA) Connecticut: Analysis of Effects on Patient Care, and Provider and Patient Satisfaction. Blood 2014, 124: 4857. DOI: 10.1182/blood.v124.21.4857.4857.Peer-Reviewed Original ResearchElectronic medical recordsHematology consultationTimeliness of careE-consultsFace visitsHematology clinicPatient satisfactionProvider satisfactionPatient careAbnormal coagulation profileMajority of patientsComprehensive electronic medical recordsPeripheral blood smearUnnecessary patient visitsNumber of veteransHealthcare delivery methodsVenous thromboembolismMedical chartsCoagulation profileRetrospective reviewAddition patientsPatient preferencesMedical recordsPatient visitsIron indicesEffect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS).
Wadia R, Yao X, Deng Y, Li J, Maron S, Connery D, Gunduz-Bruce H, Rose M. Effect of pre-existing mental health comorbidities (MHC) on stage and timeliness of care of solid tumors in Veterans Affairs Connecticut Healthcare System (VACHS). Journal Of Clinical Oncology 2014, 32: 6542-6542. DOI: 10.1200/jco.2014.32.15_suppl.6542.Peer-Reviewed Original Research
2012
EMR-linked cancer tracker facilitates lung and liver cancer care.
Taddei T, Hunnibell L, DeLorenzo A, Rosa M, Connery D, Vogel D, Garla V, Taylor C, Rose M. EMR-linked cancer tracker facilitates lung and liver cancer care. Journal Of Clinical Oncology 2012, 30: 77-77. DOI: 10.1200/jco.2012.30.34_suppl.77.Peer-Reviewed Original ResearchTracking systemAbnormal imagesLung cancerNatural language processing programNLP technologySurveillance featuresNLP systemsCancer careHepatocellular carcinomaLiver cancerVA Connecticut Healthcare SystemReporting functionsStage I/II lung cancerProcessing programCase discoveryLiver cancer careCare coordination programMultidisciplinary cancer careLive linkAccuracy of identificationElectronic medical recordsDaily operationsPatient informationRadiology reportsCare navigatorsTimeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center.
Alsamarai S, Chao H, Yao X, Deng Y, Rose M. Timeliness of care and stage at diagnosis of non-small cell lung cancer (NSCLC) with the implementation of a cancer care coordination program (CCCP) at a VA medical center. Journal Of Clinical Oncology 2012, 30: 6033-6033. DOI: 10.1200/jco.2012.30.15_suppl.6033.Peer-Reviewed Original ResearchNon-small cell lung cancerTimeliness of careLung cancerEarly-stage lung cancerVeterans Affairs Connecticut Healthcare SystemPercent of patientsInitiation of therapyRetrospective cohort analysisCare coordination programCancer-related symptomsInitiation of treatmentCell lung cancerPrimary care providersStage lung cancerVA Medical CenterAbnormal imagingNSCLC careNSCLC patientsInitial imagingPatient satisfactionMean intervalMedical CenterCohort analysisAbnormal imagesCare providers